Quality of life assessed for first time in dermatology study

12 April 2023

The protocol for the POSITIVE study, the first clinical study in dermatology to assess patients’ wellbeing as a primary endpoint, has been published in the British Medical Journal.

This study is aimed at capturing patients’ overall wellbeing in a real-world setting when in treatment with tildrakizumab, an anti-interleukin (IL)-23p19 biologic indicated for moderate-to-severe plaque psoriasis that. Branded as Ilumya and Ilumetri, the drug is marketed by Spanish drugmaker Almirall (BME: ALM) in Europe and by India’s Sun Pharmaceutical Industries (BSE: 524715) elsewhere.

Until now, overall patient wellbeing and the holistic, person-centered approach to healthcare has never been measured in a robust prospective psoriasis study.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK